#United States #Cancer Research #Pittsburgh #Allegheny Health Network #Biomarker Moonshot

Allegheny Health Network's Biomarker Moonshot Program Reaches a Major Milestone

Pittsburgh, June 12, 2026 — The Allegheny Health Network (AHN) Cancer Institute has achieved a significant milestone in their Biomarker Moonshot Cancer Research Program, surpassing the enrollment of 11,000 patients. This accomplishment highlights five years of continuous effort towards revolutionizing the ways in which cancer is detected, monitored, and treated within the comprehensive health system.

Launched in late 2020, the Biomarker Moonshot initiative has been pivotal in gathering extensive real-world cancer data and biological specimens, creating a robust repository within a community-based healthcare framework. Its primary goal is to harness genomic, clinical, and longitudinal data derived from both blood and tissue samples, which accelerates discoveries that will directly affect patient care.

Dr. David Bartlett, chair of the AHN Cancer Institute and president of the AHN Research Institute, expressed pride in reaching these impressive numbers: “Our enrollment of over 11,000 patients is a testament to the extraordinary dedication of our teams and the generosity of the participants. Our focus on all cancer types and our commitment to following each patient from diagnosis through treatment allows us to construct a powerful dataset that drives notable advancements in patient care. We are moving towards a personalized treatment approach that goes beyond traditional methods.”

As of now, the program is enrolling around 250 patients monthly from more than 30 clinical sites within AHN. This wide-reaching initiative encompasses various types of cancer, including breast, lung, colorectal, ovarian, and more, ensuring comprehensive representation across the cancer spectrum.

At the heart of the Moonshot initiative lies the analysis of circulating tumor DNA (ctDNA). This technique involves studying small fragments of cancerous DNA present in the bloodstream, which aids in understanding the progression of the disease over time. Patients who consent to join the study contribute routine blood tests and leftover surgical tissue samples, which undergo detailed genomic analysis. The insights gathered from these tests are then used in conjunction with electronic medical records to develop a deep, longitudinal perspective of a patient’s cancer journey.

Such an approach enables healthcare providers to:

• - Detect molecular residual disease post-surgery
• - Assess treatment responses more rapidly than through standard imaging techniques
• - Monitor disease progression or potential recurrences
• - Determine more individualized treatment plans based on the patient’s unique genomic profile

Since its inception, the Moonshot program has facilitated numerous research endeavors, leading to peer-reviewed publications, presentations at national conferences, and partnerships with various academic and industry leaders. These projects emphasize early detection, treatment efficacy, and ongoing disease monitoring, setting a solid foundation for the future of cancer research.

Looking ahead, the initiative aims to expand its research into high-risk populations, striving to promote earlier cancer detection and prevention methods. AHN’s leadership emphasizes the Moonshot program's essential role in their mission of delivering innovative and high-quality cancer care grounded in real-world evidence.

Dr. Bartlett closed with a poignant reminder: “Every data point represents a person and a story. We are committed to ensuring these stories help innovate better outcomes not only for current patients but for future generations.”

About Allegheny Health Network

The Allegheny Health Network is an integrated healthcare system based in western Pennsylvania that services patients across a five-state area, including regions of Ohio, West Virginia, Maryland, and New York. The network’s Cancer Institute comprises over 200 physicians and 500 oncology professionals dedicated to providing comprehensive cancer care at 24 affiliated clinics, utilizing cutting-edge technologies and a multitude of clinical trials. Recognized for its rigorous standards, the Cancer Institute is accredited by prestigious organizations, affirming its commitment to quality outcomes in cancer treatment.